Statement Of Cash Flows [Abstract]
| Concept |
2023-01-01 to 2023-12-31 |
2022-01-01 to 2022-12-31 |
|---|---|---|
| Statement of cash flows [abstract] | ||
| Cash flows from (used in) operating activities [abstract] | ||
| Adjustments for finance income (cost) |
173,000,000
EUR
|
151,000,000
EUR
|
| Increase (decrease) in working capital |
300,000,000
EUR
|
461,000,000
EUR
|
| Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss |
1,303,000,000
EUR
|
635,000,000
EUR
|
| Adjustments for gains (losses) on change in fair value less costs to sell, biological assets |
209,000,000
EUR
|
195,000,000
EUR
|
| Adjustments for undistributed profits of investments accounted for using equity method |
136,000,000
EUR
|
221,000,000
EUR
|
| Cash flows from (used in) investing activities [abstract] | ||
| Purchase of interests in investments accounted for using equity method |
5,000,000
EUR
|
7,000,000
EUR
|
| Proceeds from sales of investments accounted for using equity method |
0
EUR
|
10,000,000
EUR
|
| Purchase of biological assets |
92,000,000
EUR
|
101,000,000
EUR
|
| Purchase of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets |
897,000,000
EUR
|
603,000,000
EUR
|
| Proceeds from disposals of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets |
47,000,000
EUR
|
17,000,000
EUR
|
| Cash flows from (used in) financing activities [abstract] | ||
| Proceeds from non-current borrowings |
2,006,000,000
EUR
|
366,000,000
EUR
|